Blood Regulations: Health Canada
Thursday, 02 July 2015 16:30
MLTs should be aware that effective September 1st, 2015, adverse recipient reactions are to be submitted to the Canada Vigilance Program of the Marketed Health Products Directorate in accordance with Sections 110-115 of the Blood Regulations.
The Canada Vigilance Program is Health Canada’s post-market surveillance program that is responsible for the collection, management and assessment of adverse reaction reports. Click here (PDF) for reporting details.
The Canada Vigilance Program is Health Canada’s post-market surveillance program that is responsible for the collection, management and assessment of adverse reaction reports. Click here (PDF) for reporting details.
